Baricitinib (Olumiant) for severe alopecia areata.
出版信息
Med Lett Drugs Ther. 2022 Sep 5;64(1658):139-141.
PMID:36094552
Abstract
摘要
相似文献
1
Baricitinib (Olumiant) for severe alopecia areata.巴瑞替尼（欧陆明）用于重度斑秃。
Med Lett Drugs Ther. 2022 Sep 5;64(1658):139-141.
2
Ritlecitinib (Litfulo) for severe alopecia areata.利特昔替尼（Litfulo）用于治疗重度斑秃。
Med Lett Drugs Ther. 2023 Nov 27;65(1690):185-186. doi: 10.58347/tml.2023.1690a.
3
Baricitinib Therapy for Moderate to Severe Alopecia Areata: A Retrospective Review of 95 Japanese Patients.巴瑞替尼治疗中度至重度斑秃：对95例日本患者的回顾性研究
Acta Derm Venereol. 2024 Jan 22;104:adv18348. doi: 10.2340/actadv.v104.18348.
4
Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study.口服Janus激酶抑制剂巴瑞替尼治疗成人生斑秃的疗效和安全性：一项随机对照研究的2期结果
J Am Acad Dermatol. 2021 Oct;85(4):847-853. doi: 10.1016/j.jaad.2021.05.050. Epub 2021 Jun 16.
5
Two Phase 3 Trials of Baricitinib for Alopecia Areata.两项关于巴瑞替尼治疗斑秃的3期试验。
N Engl J Med. 2022 May 5;386(18):1687-1699. doi: 10.1056/NEJMoa2110343. Epub 2022 Mar 26.
6
Case report: Sequential therapy with dupilumab and baricitinib for severe alopecia areata with atopic dermatitis in children.病例报告：度普利尤单抗和巴瑞替尼序贯疗法治疗儿童伴有特应性皮炎的重症斑秃。
Front Immunol. 2024 Jun 6;15:1395288. doi: 10.3389/fimmu.2024.1395288. eCollection 2024.
7
Treatment of moderate-to-severe alopecia areata in patients over the age of 65 years with baricitinib.巴瑞替尼治疗 65 岁以上中重度斑秃患者。
Clin Exp Dermatol. 2024 Jul 19;49(8):875-878. doi: 10.1093/ced/llae033.
8
Characteristics of adverse event reporting of Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to the US Food and Drug Administration.向美国食品药品监督管理局报告的Xeljanz/Xeljanz XR、Olumiant和Rinvoq不良事件的特征。
J Manag Care Spec Pharm. 2022 Sep;28(9):1046-1052. doi: 10.18553/jmcp.2022.28.9.1046.
9
Baricitinib for the treatment of alopecia areata in adults: Real-world analysis of 36 patients.巴瑞替尼治疗成人斑秃：36例患者的真实世界分析。
J Am Acad Dermatol. 2024 May;90(5):1059-1061. doi: 10.1016/j.jaad.2023.09.089. Epub 2024 Jan 20.
10
Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2.斑秃患者巴瑞替尼的长期疗效和安全性：BRAVE-AA1 和 BRAVE-AA2 的 104 周结果。
J Eur Acad Dermatol Venereol. 2024 Mar;38(3):583-593. doi: 10.1111/jdv.19665.
Zotero 插件